data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
Watch
YouTube
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Athenex
(NASDAQ:ATNX)
Athenex, Inc. - Common Stock is expected to split Monday, August 15, 2022 with a ratio of 1:5
Athenex, Inc. - Common Stock recently split on Friday, August 12, 2022 with a ratio of 1:3
$0.52
-0.0179[-3.33%]
At close: Aug 12
$0.534
0.0140[2.69%]
After Hours: 6:51PM EDT
Day High/Low0.52 - 0.56
52 Week High/Low0.41 - 1.66
Open / Close0.55 / 0.52
Float / Outstanding99.7M / 121.6M
Vol / Avg.6.2M / 1.9M
Mkt Cap63.2M
P/E-
50d Avg. Price0.58
Div / Yield-
Payout Ratio-
EPS-0.28
Total Float99.7M

Athenex (NASDAQ:ATNX), Quotes and News Summary

Athenex (NASDAQ: ATNX)

Day High/Low0.52 - 0.56
52 Week High/Low0.41 - 1.66
Open / Close0.55 / 0.52
Float / Outstanding99.7M / 121.6M
Vol / Avg.6.2M / 1.9M
Mkt Cap63.2M
P/E-
50d Avg. Price0.58
Div / Yield-
Payout Ratio-
EPS-0.28
Total Float99.7M
Sector: Health Care.Industry: Biotechnology
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.
Read More

Earnings

see more
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-12-20
REV
FY 2023Est.ActualSurprise
EPS
(EXPECTED)2023-11-09
REV

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Athenex Questions & Answers

Q
How do I buy Athenex (ATNX) stock?
A

You can purchase shares of Athenex (NASDAQ: ATNX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Athenex's (ATNX) competitors?
Q
What is the target price for Athenex (ATNX) stock?
A

The latest price target for Athenex (NASDAQ: ATNX) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting ATNX to rise to within 12 months (a possible 669.23% upside). 50 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Athenex (ATNX)?
A

The stock price for Athenex (NASDAQ: ATNX) is $0.52 last updated August 12, 2022, 8:00 PM UTC.

Q
Does Athenex (ATNX) pay a dividend?
A

The next Athenex (ATNX) dividend date is projected to be Thursday, September 1, 2022.

Q
When is Athenex (NASDAQ:ATNX) reporting earnings?
A

Athenex’s FY earnings are confirmed for Wednesday, December 20, 2023.

Q
Is Athenex (ATNX) going to split?
A

There is no upcoming split for Athenex.

Q
What sector and industry does Athenex (ATNX) operate in?
A

Athenex is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.